The Malaysian Clinical Guidance on the Management of Postmenopausal Osteoporosis, 2012: A Summary
Corresponding Author
Swan S. Yeap
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Correspondence: Dr Swan S. Yeap, Consultant Rheumatologist, Sime Darby Medical Centre Subang Jaya, No. 1, Jalan SS 12/1A, 47500 Subang Jaya, Selangor, Malaysia.
Email: [email protected]
Search for more papers by this authorFen L. Hew
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorJoon K. Lee
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorEmily M. L. Goh
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorWinnie Chee
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorMalik Mumtaz
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorPremitha Damodaran
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorHeng H. Lim
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorSiew P. Chan
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorCorresponding Author
Swan S. Yeap
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Correspondence: Dr Swan S. Yeap, Consultant Rheumatologist, Sime Darby Medical Centre Subang Jaya, No. 1, Jalan SS 12/1A, 47500 Subang Jaya, Selangor, Malaysia.
Email: [email protected]
Search for more papers by this authorFen L. Hew
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorJoon K. Lee
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorEmily M. L. Goh
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorWinnie Chee
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorMalik Mumtaz
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorPremitha Damodaran
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorHeng H. Lim
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorSiew P. Chan
The Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis, 2012
Search for more papers by this authorAbstract
Aim
This Clinical Guidance is aimed to help practitioners assess, diagnose and manage their patients with osteoporosis (OP), using the best available evidence.
Methods
A literature search using PubMed (MEDLINE) and The Cochrane Library identified all relevant articles on OP and its assessment, diagnosis and treatment, from 2005, to update from the previous edition published in 2006. The studies were assessed and the level of evidence assigned; for each statement, studies with the highest level of evidence were used to frame the recommendation.
Results
This article summarizes the diagnostic and treatment pathways for OP, highlighting the new data that have changed the way we assess and treat OP. Instead of starting treatment based on bone mineral density alone, there has been a move to assessing 10-year fracture risk before treatment, using tools such as the Fracture Risk Assessment Tool (FRAX). There has been a re-evaluation on calcium supplementation and more emphasis on the importance of vitamin D. There has been concern about the potential adverse effects of the long-term usage of bisphosphonates, which we have discussed fully. New drugs that have been licensed since 2006 in Malaysia have been included.
Conclusions
Adequate intake of calcium (1000 mg from both diet and supplements) and vitamin D (800 IU) daily remain important in the treatment of OP. However, in confirmed OP, pharmacological therapy with anti-resorptives is the mainstay of treatment. Patients need to be regularly assessed while on medication and treatment adjusted as required.
References
- 1 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785–95.
- 2Cooper C, Campion G, Melton LJ III (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2, 285–9.
- 3Lee JK, Khir ASM (2007) The incidence of hip fracture in Malaysians above 50 years of age: variation in different ethnic groups. APLAR J Rheumatol 10, 300–5.
10.1111/j.1479-8077.2007.00314.x Google Scholar
- 4Shekelle PG, Woolf SH, Eccles M, Grimshaw J (1999) clinical guidelines: Developing guidelines. BMJ 318, 593–6.
- 5Harbour R, Miller J, for the Scottish Intercollegiate Guidelines Network Grading Review Group (2001) A new system for grading recommendations in evidence based guidelines. BMJ 323, 334–6.
- 6Koh LKH, Sedrine WB, Torraba TP et al. (2001) On behalf of the Osteoporosis Self-Assessment Tool for Asians (OSTA) Research Group. A simple tool to identify Asian women at increased risk of Osteoporosis. Osteoporos Int 12, 699–705.
- 7Lewiecki EM, Gordon CM, Baim S et al. (2008) International society for clinical densitometry 2007 adult and pediatric official positions. Bone 43, 1115–21.
- 8 WHO technical report series 843 (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. Geneva, World Health Organisation.
- 9Vasikaran S, Eastell R, Bruyère O et al. (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22, 391–420.
- 10Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929–36.
- 11Kanis JA, Johnell O, Oden A et al. (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19, 385–97.
- 12FRAX: WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX (accessed 31 December 2012).
- 13 National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis January 2010. http://www.nof.org/sites/default/files/pdfs/NOF_Clinician Guide2009_v7.pdf (accessed 22 March 2012).
- 14Chang JT, Morton SC, Rubenstein LZ et al. (2004) Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. BMJ 328, 680–3.
- 15Body J-J, Bergmann P, Boonen S et al. (2011) Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int 22, 2769–88.
- 16 National Coordinating Committee on Food and Nutrition (2005). Recommended Nutrient Intakes for Malaysia. Ministry of Health, Malaysia.
- 17Bolland MJ, Avenell A, Baron JA et al. (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341, c3691.
- 18Bolland MJ, Grey A, Avenell A et al. (2011) Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 342, d2040.
- 19Lewis JR, Calver J, Zhu K, Flicker L, Prince RL (2011) Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 26, 35–41.
- 20Avenell A, MacLennan GS, Jenkinson DJ et al. (2012) Long-term follow-up for mortality and cancer in a randomized placebo-controlled Trial of vitamin D3 and/or calcium (RECORD trial). J Clin Endocrinol Metab 97, 614–22.
- 21Gibson RA, Makrides M, Smithers LG et al. (2009) The effect of dairy foods on CHD: a systematic review of prospective cohort studies. Br J Nutr 102, 1267–75.
- 22Green JH, Booth C, Bunning R (2003) Acute effect of high-calcium milk with or without additional magnesium, or calcium phosphate on parathyroid hormone and biochemical markers of bone resorption. Eur J Clin Nutr 57, 61–8.
- 23Reid IR, Bolland MJ, Avenell A et al. (2011) Cardiovascular effects of calcium supplementation. Osteoporos Int 22, 1649–58.
- 24Ross AC, Manson AE, Abrams SA et al. (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 96, 53–8.
- 25Holick MF, Binkley NC, Bischoff-Ferrari HA et al. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96, 1911–30.
- 26Shane E, Burr D, Ebeling PR, Abrahamsen B et al. (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25, 2267–94.
- 27Rizzoli R, Åkesson K, Bouxsein M et al. (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 22, 373–90.
- 28Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fracture of the femoral shaft. N Engl J Med 364, 1728–37.
- 29Park-Wyllie LY, Mamdani MM, Juurlink DN et al. (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305, 783–9.
- 30 Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons (2007) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65, 369–76.
- 31Khan AA, Sándor GKB, Dore E et al. (2009) Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 36, 478–90.
- 32Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65, 415–23.
- 33 American Dental Association Council on Scientific Affairs (2006) Expert panel recommendations: dental management of patients receiving oral bisphosphonate therapy. J Am Dental Assoc 137, 1144–50.
- 34Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ (2012) Continuing bisphosphonate treatment for osteoporosis – for whom and for how long? N Engl J Med 366, 2051–3.
- 35Black DM, Schwartz AV, Ensrud KE et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX):a randomized trial. JAMA 296, 2927–38.
- 36Howe TE, Shea B, Dawson LJ et al. (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 7: CD000333.
- 37Tang BMP, Eslick GD, Nowson C, Smith C, Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657–66.
- 38Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B et al. (2009) Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. J Bone Miner Res 24, 935–42.
- 39Jensen J, Lundin-Olsson L, Nyberg L, Gustafson Y (2002) Fall and injury prevention in older people living in residential care facilities. A cluster randomized trial. Ann Intern Med 136, 733–41.
- 40Cauley JA, Robbins J, Chen Z, for the Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729–38.
- 41Delmas PD, Bjarnason NH, Mitlak BH et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337, 1641–7.
- 42Kanis JA, Johnell O, Black DM et al. (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33, 293–300.
- 43Hosking D, Chilvers CE, Christiansen C et al. (1998) Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med 338, 485–92.
- 44Wells GA, Cranney A, Peterson J et al. (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev Jan 23; (1): CD001155.
- 45Cummings SR, Ettinger B, Delmas PD, for the LIFT Trial Investigators et al. (2008) The effects of Tibolone in older post menopausal women. N Eng J Med 359, 697–708.
- 46Black DM, Cummings SR, Karpf DB et al. (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (9041), 1535–41.
- 47Cummings SR, Black DM, Thompson DE et al. (1998) For the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280, 2077–82.
- 48Chesnut CH III, Skag A, Christiansen C et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19, 1241–9.
- 49Reginster JY, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis (VERT). Osteoporosis Int 11, 83–91.
- 50Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post menopausal osteoporosis: a randomized controlled trial (VERT). JAMA 282, 1344–52.
- 51McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344, 333–40.
- 52Black DM, Delmas PD, Eastell R et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356, 1809–22.
- 53Meunier PJ, Roux C, Seeman E et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Eng J Med 350, 459–68.
- 54O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 3, CD005326.
- 55Cummings SR, Martin JS, McClung MR et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361, 756–65.
- 56Neer RM, Arnaud CD, Zanchetta JR et al. (2001) Effect of parathyroid hormone (1–34) on fracture and bone mineral density in postmenopausal women with osteoporosis. N Engl J. Med 334, 1434–41.
- 57Delmas PD, Ensrud KE, Adachi JD et al. (2003) Efficacy of raloxifene in vertebral fracture risk reduction in postmenopausal women with osteoporosis. Four year results from a randomized clinical trial. J Clin Endocrinol Metab 87, 3609–17.
- 58Chesnut CH, Silverman S, Andriano K et al. (2000) A randomised trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fracture study. Am J Med 109, 267–76.
- 59Orimo H, Shiraki M, Hayashi Y et al. (1994) Effects of 1a-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54, 370–6.
- 60Tilyard MW, Spears GF, Thomson J et al. (1992) Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326, 357–62.
- 61Chapuy MC, Arlot ME, Duboeuf F et al. (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327, 1637–42.
- 62Miller PD, McClung MR, Macovei L et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20, 1315–22.
- 63Tee ES, Ismail MN, Nasir A, Khatijah I (1997) Nutrient composition of Malaysian foods. Malaysian Food Composition Database Program c/o Institute for Medical Research Kuala Lumpur.
